Picone F P, Lombardo A, Rapisarda L M, Giambruno M, Gerosa C, Nazzari M
Istituto di Patologia Chirurgica, Università degli Studi di Palermo.
Minerva Med. 1991 Apr;82(4):177-80.
Twenty patients, submitted to internal arteriovenous fistula procedure, were randomly assigned to one of the following treatments: defibrotide 400 mg b.i.d. IM (starting the day before surgery and continuing for the following 7 days); calcium heparin 5,000 IU t.i.d. SC (since the day of surgery and for the following 7 days). No deep venous thrombosis or thrombosis of the fistula were noticed during both treatments and no side effects were observed. In the defibrotide group, ELT showed a significant decrease (-40%) attesting an improvement of fibrinolysis without a plasminogen abatement. These findings indicate that defibrotide represent an effective alternative to calcium heparin for antithrombotic prophylaxis of A-V fistula in uremic patients.
去纤苷400毫克，每日两次，肌肉注射（手术前一天开始，持续7天）；肝素钙5000国际单位，每日三次，皮下注射（自手术当天起，持续7天）。两种治疗期间均未发现深静脉血栓形成或瘘管血栓形成，也未观察到副作用。在去纤苷组中，优球蛋白溶解时间显著缩短（-40%），证明纤溶改善而纤维蛋白原无减少。这些发现表明，去纤苷是尿毒症患者动静脉瘘抗血栓预防中肝素钙的有效替代药物。
